Level of Anticitrullinated Peptide/Protein Antibody Is Not Associated with Lung Diseases in Rheumatoid Arthritis

Article Figures & Data

Table 1.

Distribution of lung disease in ACPA-positive patients with RA.

↵* Rheumatic lung disease includes interstitial pulmonary fibrosis, bronchiectasis, and rheumatoid nodules.
↵** Includes pulmonary involvement such as tuberculosis, atelectasis, pneumonia, focal inflammation, excepting rheumatic lung diseases. ACPA: anticitrullinated peptide/protein antibody; RA: rheumatoid arthritis; APF: antiperinuclear factor; CCP: cyclic citrullinated peptide.

Table 2.

Median values of ACPA level according to lung disease in ACPA-positive patients with RA.

			RA with Lung Disease
Test	Patient Group	RA without Lung Disease	Rheumatic Lung Disease^*	p	Other Lung Disease^**	p
APF, by fluorescence intensity, 1–4 scale	APF+, anti-CCP+	2	2.5	0.061	2	0.856
APF, by fluorescence intensity, 1–4 scale	APF+, anti-CCP–	1.5	1	0.367	1	0.502
Anti-CCP, U/ml	Anti-CCP+, APF+	723	538	0.072	681	0.508
Anti-CCP, U/ml	Anti-CCP+, APF–	357	300	0.773	164	0.023

↵* Rheumatic lung disease includes interstitial pulmonary fibrosis, bronchiectasis, and rheumatoid nodules.
↵** Includes pulmonary involvement such as tuberculosis, atelectasis, pneumonia, focal inflammation, excepting rheumatic lung diseases. ACPA: anticitrullinated peptide/protein antibody; RA: rheumatoid arthritis; APF: antiperinuclear factor; CCP: cyclic citrullinated peptide.